'Pantys has transformed women’s relationship with menstruation'
Leaders League Brazil interviewed Emily Ewell, CEO of Pantys, an innovative Brazilian femtech that specializes in absorbent underwear. She tells us about the main characteristics o...
Nearly 10 years after Burford Capital became the first-ever litigation funder to go public in the UK, Manolete Partners has announced it plans to IPO on AIM in mid-December
Law.com
London-based litigation funder Manolete Partners has announced it is expected to be admitted on AIM on December 14. Founded in 2009, the same year that Burford Capital became the first-ever litigation funder to go public in the UK, Manolete focuses on acquiring or funding insolvency and insolvency-related claims; as of September 2018, it had invested in 249 cases and had gross recoveries of £27.9 million from 173 closed cases. The listing will give the funder a market capitalisation of £76.3 million.
Manolete’s decision comes just under two months after Vannin Capital, a major player in the litigation funding space, aborted its decision to IPO due to the volatility in the equity markets. The backing of City veteran Jon Moulton, who owned 40% of Manolete prior to its listing, no doubt helped comfort investors this time round though, with Manolete managing to raise £16.3 million before expenses from the placing of new ordinary shares and £13.1 million before expenses from the placing of existing ordinary shares.
Leaders League Brazil interviewed Emily Ewell, CEO of Pantys, an innovative Brazilian femtech that specializes in absorbent underwear. She tells us about the main characteristics o...
Luther Luxembourg continues to strengthen its Insurance and Reinsurance Department. Its newest recruit is senior associate Grégory Maricle, who brings a wealth of experience...
European authorities are concerned about the statements of Twitter's boss as well as Twitter’s drastic cuts in its means of moderating online content, particularly in the shadow of...
Leonor Pissarra, Portugal Chief Legal Officer, Novartis shares how she navigates the ever-changing regulatory environment of the pharma industry, the rise of digital health technol...